1 Kerlikowske, K. Epidemiology of ductal carcinoma in situ. Journal of the National Cancer Institute. Monographs 2010, 139-141, doi:10.1093/jncimonographs/lgq027 (2010).
2 van Steenbergen, L. N. et al. Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast cancer research and treatment 115, 181-183, doi:10.1007/s10549-008-0067-5 (2009).
3 Groen, E. J. et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast (Edinburgh, Scotland) 31, 274-283, doi:10.1016/j.breast.2016.09.001 (2017).
4 Worni, M. et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. Journal of the National Cancer Institute 107, djv263, doi:10.1093/jnci/djv263 (2015).
5 Ponti, A. et al. International variation in management of screen-detected ductal carcinoma in situ of the breast. European journal of cancer (Oxford, England : 1990) 50, 2695-2704, doi:10.1016/j.ejca.2014.07.019 (2014).
6 Wang, S. Y., Shamliyan, T., Virnig, B. A. & Kane, R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast cancer research and treatment 127, 1-14, doi:10.1007/s10549-011-1387-4 (2011).
7 Yi, M. et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, 600-607, doi:10.1200/jco.2011.36.4976 (2012).
8 Silverstein, M. J. et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77, 2267-2274, doi:10.1002/(sici)1097-0142(19960601)77:11<2267::aid-cncr13>3.0.co;2-v (1996).
9 Silverstein, M. J. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. American journal of surgery 186, 337-343, doi:10.1016/s0002-9610(03)00265-4 (2003).
10 Silverstein, M. J. & Lagios, M. D. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. Journal of the National Cancer Institute. Monographs 2010, 193-196, doi:10.1093/jncimonographs/lgq040 (2010).
11 Silverstein, M. J. & Lagios, M. D. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. The breast journal 21, 127-132, doi:10.1111/tbj.12368 (2015).
12 Rakovitch, E. et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast cancer research and treatment 152, 389-398, doi:10.1007/s10549-015-3464-6 (2015).
13 Nofech-Mozes, S., Hanna, W. & Rakovitch, E. Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. The American journal of pathology 189, 975-980, doi:10.1016/j.ajpath.2018.12.003 (2019).
14 Punglia, R. S. et al. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast cancer research and treatment 167, 751-759, doi:10.1007/s10549-017-4553-5 (2018).
15 Whitfield, R., Kollias, J., de Silva, P., Turner, J. & Maddern, G. Management of ductal carcinoma in situ according to Van Nuys Prognostic Index in Australia and New Zealand. ANZ journal of surgery 82, 518-523, doi:10.1111/j.1445-2197.2012.06133.x (2012).
16 Variation in the management of ductal carcinoma in situ in the UK: Results of the Mammary Fold National Practice Survey. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 42, 1153-1161, doi:10.1016/j.ejso.2016.05.024 (2016).
17 Gilleard, O., Goodman, A., Cooper, M., Davies, M. & Dunn, J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World journal of surgical oncology 6, 61, doi:10.1186/1477-7819-6-61 (2008).
18 Boland, G. P., Chan, K. C., Knox, W. F., Roberts, S. A. & Bundred, N. J. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. The British journal of surgery 90, 426-432, doi:10.1002/bjs.4051 (2003).
19 MacAusland, S. G. et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110, 2648-2653, doi:10.1002/cncr.23089 (2007).
20 Di Saverio, S. et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast cancer research and treatment 109, 405-416, doi:10.1007/s10549-007-9668-7 (2008).
21 Solin, L. J. Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. Current oncology reports 21, 33, doi:10.1007/s11912-019-0777-3 (2019).
22 Gorringe, K. L. & Fox, S. B. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Frontiers in oncology 7, 248, doi:10.3389/fonc.2017.00248 (2017).
23 Buchholz, T. A., Haffty, B. G. & Harris, J. R. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. Journal of surgical oncology 95, 610-613, doi:10.1002/jso.20711 (2007).
24 Morrow, M. et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 4040-4046, doi:10.1200/jco.2016.68.3573 (2016).
25 Wapnir, I. L. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Journal of the National Cancer Institute 103, 478-488, doi:10.1093/jnci/djr027 (2011).
26 Donker, M. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, 4054-4059, doi:10.1200/jco.2013.49.5077 (2013).
27 Wärnberg, F. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, 3613-3618, doi:10.1200/jco.2014.56.2595 (2014).
28 Cuzick, J. et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. The Lancet. Oncology 12, 21-29, doi:10.1016/s1470-2045(10)70266-7 (2011).
29 McCormick, B. et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, 709-715, doi:10.1200/jco.2014.57.9029 (2015).
30 Goodwin, A., Parker, S., Ghersi, D. & Wilcken, N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. The Cochrane database of systematic reviews, Cd000563, doi:10.1002/14651858.CD000563.pub7 (2013).